[6-K] Haleon plc American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc has filed a Form 6-K outlining the latest activity under the second tranche of its share-buyback programme announced on 31 July 2025.

On 6 Aug 2025 the company repurchased 1,517,728 ordinary shares on the London Stock Exchange at a volume-weighted average price of 347.5568 p (high 350.3000 p, low 346.3000 p). No shares were bought on Cboe BXE or CXE. All acquired shares will be cancelled.

Post-transaction, Haleon’s issued share capital totals 8,981,923,508 shares of £0.01 each, with 3,880,205 held in treasury, leaving 8,978,043,303 voting shares outstanding. The purchase equates to roughly 0.017 % of shares in issue and does not materially alter the company’s capital structure.

No earnings figures, guidance, or other material financial disclosures accompany this filing. The update is chiefly administrative, confirming incremental progress toward the ongoing buyback plan.

Insights

Financial Analyst

TL;DR: Small buyback (0.017% of shares) — positive signal but financially immaterial; neutral impact on valuation.

The 1.52 million-share repurchase demonstrates management’s commitment to capital return but represents a negligible fraction of the 8.98 billion shares outstanding. At ~347.6 p per share, the cash outlay is about £5.3 million, minor relative to Haleon’s market capitalisation. Because the shares are cancelled, future EPS is fractionally accretive, yet the impact is too small to shift consensus estimates or credit metrics. The filing contains no updates on operations, guidance, or liquidity, limiting its relevance to buy-side models. Overall, the action is directionally positive for shareholder returns but does not materially influence investment thesis or risk profile.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	07 August 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

07 August 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 1,517,728 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	06 August 2025	06 August 2025	06 August 2025
Number of Shares purchased:	1,517,728	-	-
Highest price paid per Share (p):	350.3000	-	-
Lowest price paid per Share (p):	346.3000	-	-
Volume weighted average price paid per Share (p):	347.5568	-	-

Following the settlement of the above, the Company's registered share capital is 8,981,923,508 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,978,043,303 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/3105U_1-2025-8-6.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: August 07, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

How many Haleon (HLN) shares were repurchased in the August 2025 Form 6-K?

The company bought 1,517,728 ordinary shares on 6 August 2025.

What was the average price paid per repurchased Haleon share?

The volume-weighted average price was 347.5568 p per share.

What is Haleon’s updated number of voting shares after the buyback?

Voting shares outstanding now total 8,978,043,303.

Does the 6-K include any new earnings or guidance information for HLN?

No. The filing is limited to the share-buyback transaction and contains no earnings or guidance updates.

Where can investors find the detailed trade breakdown for Haleon’s buyback?

A full list of individual trades is available at http://www.rns-pdf.londonstockexchange.com/rns/3105U_1-2025-8-6.pdf.